Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGFR‐TKIs and prognostic factors for patients with NSCLC...

Full description

Bibliographic Details
Main Authors: John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Thoracic Cancer
Subjects:
afatinib
erlotinib
gefitinib
lung cancer
uncommon mutation
Online Access:https://doi.org/10.1111/1759-7714.14537

Internet

https://doi.org/10.1111/1759-7714.14537

Similar Items